Skip to main content
SpringerLink
Log in

Using the Bleomycin-Induced Model of Fibrosis to Study the Contribution of CCN Proteins to Scleroderma Fibrosis

  • Protocol
  • First Online:
CCN Proteins

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2582))

  • 673 Accesses

Abstract

Approximately 45% of the deaths in the developed world result from conditions with a fibrotic component. Although no specific, focused anti-fibrotic therapies have been approved for clinical use, a long-standing concept is that targeting CCN proteins may be useful to treat fibrosis. Herein, we summarize current data supporting the concept that targeting CCN2 may be a viable anti-fibrotic approach to treat scleroderma. Testing this hypothesis has been made possible by using a mouse model of inflammation-driven skin and lung fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kielty CM, Shuttleworth CA (1997) Microfibrillar elements of the dermal matrix. Microsc Res Tech 38(4):413–427

    Article  CAS  PubMed  Google Scholar 

  2. Singer AJ, Clark RAF (2008) Cutaneous wound healing. N Engl J Med 341(10):738–746

    Article  Google Scholar 

  3. Gabbiani G, Ryan G, Majne G (1971) Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27(5):549–550. https://doi.org/10.1007/BF02147594

    Article  CAS  PubMed  Google Scholar 

  4. Hinz B (2010) The myofibroblast: paradigm for a mechanically active cell. J Biomech. https://doi.org/10.1016/j.jbiomech.2009.09.020

  5. Walraven M, Hinz B (2018) Therapeutic approaches to control tissue repair and fibrosis: extracellular matrix as a game changer. Matrix Biol 71–72:205–224. https://doi.org/10.1016/J.MATBIO.2018.02.020

    Article  PubMed  Google Scholar 

  6. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199–210. https://doi.org/10.1002/path.2277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J (2015) Systemic sclerosis. Nat Rev Dis Primers 1(15002):1–21. https://doi.org/10.1038/nrdp.2015.2

    Article  Google Scholar 

  8. Volkmann ER, Varga J (2019) Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol 15(4):208–224

    Article  PubMed  Google Scholar 

  9. Leask A (2015) Matrix remodeling in systemic sclerosis. Semin Immunopathol 37:559

    Article  CAS  PubMed  Google Scholar 

  10. Denton CP, Wells AU, Coghlan JG (2018) Major lung complications of systemic sclerosis. Nat Rev Rheumatol 14(9):511–527

    Article  PubMed  Google Scholar 

  11. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989–2003

    Article  CAS  PubMed  Google Scholar 

  12. Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15(7):753–764

    Article  CAS  PubMed  Google Scholar 

  13. Stern EP, Denton CP (2015) The pathogenesis of systemic sclerosis. Rheum Dis Clin N Am 41(3):367–382

    Article  Google Scholar 

  14. Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML (2017) A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med 9(1):27

    Article  PubMed  PubMed Central  Google Scholar 

  15. King J, Abraham D, Stratton R (2018) Chemokines in systemic sclerosis. Immunol Lett 195:68–75

    Article  CAS  PubMed  Google Scholar 

  16. Wang Y, Fan P-S, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheumatol 54(7):2271–2279

    Article  CAS  Google Scholar 

  17. Chen Y, Shi-Wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ, Xu SW, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ (2006) Contribution of activin receptor-like kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheumatol 54(4):1309–1316

    Article  CAS  Google Scholar 

  18. Leask A (2020) Conjunction junction, what’s the function? CCN proteins as targets in fibrosis and cancers. Am J Physiol Cell Physiol 318(6):C1046–C1054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G (1993) Transforming growth factor-β 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122(1):103–111

    Article  PubMed  Google Scholar 

  20. Hinz B, McCulloch CA, Coelho NM (2019) Mechanical regulation of myofibroblast phenoconversion and collagen contraction. Exp Cell Res 379(1):119–128

    Article  CAS  PubMed  Google Scholar 

  21. Hinz B (2016) The role of myofibroblasts in wound healing. Curr Res Transl Med 64(4):171–177

    Article  CAS  PubMed  Google Scholar 

  22. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500–503

    Article  CAS  PubMed  Google Scholar 

  23. Leask A (2021) The hard problem: Mechanotransduction perpetuates the myofibroblast phenotype in scleroderma fibrosis. Wound Repair Regen 29:582–587

    Article  PubMed  Google Scholar 

  24. Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, Yamamura K, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M (2011) Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Investig 121(10):3981–3990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tsang M, Quesnel K, Vincent K, Hutchenreuther J, Postovit L-M, Leask A (2019) Insights into fibroblast plasticity: cellular communication network 2 is required for activation of cancer-associated fibroblasts in a Murine Model of melanoma. Am J Pathol 190(1):206–221

    Article  PubMed  Google Scholar 

  26. Humphreys BD, Lin S-L, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Todd Valerius M, McMahon AP, Duffield JS (2010) Epithelial and mesenchymal cell biology fate tracing reveals the Pericyte and not epithelial origin of Myofibroblasts in kidney fibrosis. Am J Pathol 176:85–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hung C, Linn G, Chow Y-H, Kobayashi A, Mittelsteadt K, Altemeier WA, Gharib SA, Schnapp LM, Duffield JS (2013) Role of lung Pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 188(7):820–830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dulauroy S, di Carlo SE, Langa F, Eberl G, Peduto L (2012) Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med 18(8):1262–1270

    Article  CAS  PubMed  Google Scholar 

  29. Joe AWB, Yi L, Natarajan A, Grand F le, So L, Wang J, Rudnicki MA, Rossi FMV (2010) Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 12(2):163

    Article  Google Scholar 

  30. Contreras O, Rossi FM, Brandan E (2019) Adherent muscle connective tissue fibroblasts are phenotypically and biochemically equivalent to stromal fibro/adipogenic progenitors. Matrix Biol Plus 2:100006

    Article  PubMed  PubMed Central  Google Scholar 

  31. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676

    Article  CAS  PubMed  Google Scholar 

  32. Kane CJM, Hebda PA, Mansbridge JN, Hanawalt PC (1991) Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing. J Cell Physiol 148(1):157–173

    Article  CAS  PubMed  Google Scholar 

  33. Kissin EY, Lemaire R, Korn JH, Lafyatis R (2002) Transforming growth factor β induces fibroblast fibrillin-1 matrix formation. Arthritis Rheumatol 46(11):3000–3009

    Article  CAS  Google Scholar 

  34. Malmstrom J, Linberg H, Lindberg C, Bratt C, Wieslander E, Delander EL, Särnstrand B, Burns JS, Mose-Larsen P, Fey S, Marko-Varga G (2004) Transforming growth factor-β1 specifically induce proteins involved in the Myofibroblast contractile apparatus. Mol Cell Proteomics 3(5):466–477

    Article  PubMed  Google Scholar 

  35. Leask A (2010) Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair 3:8

    Article  PubMed  PubMed Central  Google Scholar 

  36. Massagué J (1998) TGFβ signal transduction. Annu Rev Biochem 67:753–791

    Article  PubMed  Google Scholar 

  37. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276(14):10594–10601

    Article  CAS  PubMed  Google Scholar 

  38. Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J (2006) Intracellular TGF-β receptor blockade abrogates smad-dependent fibroblast activation in vitro and in vivo. J Investig Dermatol 126:1733–1744

    Article  CAS  PubMed  Google Scholar 

  39. Thompson K, Murphy-Marshman H, Leask A (2014) ALK5 inhibition blocks TGFβ-induced CCN1 expression in human foreskin fibroblasts. J Cell Commun Signal 8(1):59–63

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lagares D, Busnadiego O, Ana García-Fernández R, Kapoor M, Liu S, Carter DE, Abraham D, Shi-Wen X, Carreira P, Fontaine BA, Shea BS, Tager AM, Leask A, Lamas S, Rodríguez-Pascual F (2012) Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheumatol 64(5):1653–1664

    Article  CAS  Google Scholar 

  41. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM, Thomas PE (2003) Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 278(14):12384–12389

    Article  CAS  PubMed  Google Scholar 

  42. Shi-Wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ (2012) Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology 51(12):2146–2154

    Article  PubMed  Google Scholar 

  43. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S (2011) Role of YAP/TAZ in mechanotransduction. Nature 474(7350):179–183

    Article  CAS  PubMed  Google Scholar 

  44. Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation: requirements for its induction by transforming growth factor-β2 in fibroblasts. J Biol Chem 278:13008–13015

    Article  CAS  PubMed  Google Scholar 

  45. Shi-wen X, Racanelli M, Ali A, Simon A, Quesnel K, Stratton RJ, Leask A (2021) Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. J Cell Commun Signal 15(1):71–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R, Szymaniak AD, Varelas X, Trojanowska M (2018) Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J Investig Dermatol 138(1):78–88

    Article  CAS  PubMed  Google Scholar 

  47. Bornstein P (2009) Matricellular proteins: an overview. J Cell Commun Signal 3:163–165

    Article  PubMed  PubMed Central  Google Scholar 

  48. Bradshaw AD (2016) The extracellular matrix. Encyclopedia Cell Biol 2:694–703

    Article  Google Scholar 

  49. Prakoura N, Chatziantoniou C (2017) Matricellular proteins and organ fibrosis. Curr Patho-Biol Rep:1–11

    Google Scholar 

  50. Feng D, Gerarduzzi C (2020) Emerging roles of Matricellular proteins in systemic sclerosis. Int J Mol Sci 21(13):4776

    Article  CAS  PubMed Central  Google Scholar 

  51. Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119(23):4803–4810

    Article  CAS  PubMed  Google Scholar 

  52. Kubota S, Takigawa M (2013) The CCN family acting throughout the body: recent research developments. Biomol Concepts 4(5):477–494

    Article  CAS  PubMed  Google Scholar 

  53. Bradham DM, Igarashi A, Potter RL, Grotendorst GR (1991) Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114(6):1294. https://doi.org/10.1083/JCB.114.6.1285

    Article  Google Scholar 

  54. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B (1992) Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 12(1):21. https://doi.org/10.1128/MCB.12.1.10

    Article  Google Scholar 

  55. O’Brien TP, Yang GP, Sanders L, Lau LF (1990) Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 10(7):3577. https://doi.org/10.1128/MCB.10.7.3569

    Article  Google Scholar 

  56. Perbal B (2019) CCN proteins are part of a multilayer complex system: a working model. J Cell Commun Signal. 13(4):437–439

    Article  PubMed  PubMed Central  Google Scholar 

  57. Takigawa M (2018) An early history of CCN2/CTGF research: the road to CCN2 via hcs24, ctgf, ecogenin, and regenerin. J Cell Commun Signal. 12(1):253-264Perbal, B., Tweedie, S., & Bruford, E. (2018). The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1–6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1–3 respectively. J Cell Commun Signal 12(4):625–629

    Google Scholar 

  58. Perbal B (2018) The concept of the CCN protein family revisited: a centralized coordination network. J Cell Commun Signal. 12(1):3–12

    Article  PubMed  PubMed Central  Google Scholar 

  59. Lau LF (2016) Cell surface receptors for CCN proteins. J Cell Commun Signal 10(2):121–127

    Article  PubMed  PubMed Central  Google Scholar 

  60. Chen Y, Abraham DJ, Shi-Wen X, Pearson JD, Black CM, Lyons KM, Leask A (2004) CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 15:5197–5732

    Article  Google Scholar 

  61. Hoshijima M, Hattori T, Inoue M, Araki D, Hanagata H, Miyauchi A, Takigawa M (2006) CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin α5β1. FEBS Lett 580(5):1376–1382

    Article  CAS  PubMed  Google Scholar 

  62. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Investig Dermatol 106(4):729–733

    Article  CAS  PubMed  Google Scholar 

  63. Riser BL, Barnes JL, Varani J (2015) Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal 9(4):327–339

    Article  PubMed  PubMed Central  Google Scholar 

  64. Quesnel K, Shi-wen X, Hutchenreuther J, Xiao Y, Liu S, Peidl A, Naskar D, Siqueira WL, O’Gorman DB, Hinz B, Stratton RJ, Leask A (2019) CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. Matrix Biol Plus 3:100009

    Article  PubMed  PubMed Central  Google Scholar 

  65. Holmes A, Abraham DJ, Chen Y, Denton C, Shi-Wen X, Black CM, Leask A (2003) Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 278:41728–41733

    Article  CAS  PubMed  Google Scholar 

  66. Chen Y, Segarini P, Raoufi F, Bradham D, Leask A (2001) Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res 271(1):109–117

    Article  CAS  PubMed  Google Scholar 

  67. Chen CC, Chen N, Lau LF (2001) The Angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 276:10443–10452

    Article  CAS  PubMed  Google Scholar 

  68. Liu S, Shi-Wen X, Abraham DJ, Leask A (2011) CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheumatol 63(1):239–246

    Article  CAS  Google Scholar 

  69. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K (1999) Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 181:153–159

    Article  CAS  PubMed  Google Scholar 

  70. Barbe MF, Hilliard BA, Amin M, Harris MY, Hobson LJ, Cruz GE, Popoff SN (2020) Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury. FASEB J 34:6554–6569

    Article  CAS  PubMed  Google Scholar 

  71. Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A, Pföhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Gröne H-J, Nicolay NH, Saffrich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE (2017) Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J Natl Cancer Inst 109(8). https://doi.org/10.1093/JNCI/DJW339

  72. Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M (2017) Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res Ther 19(1):134

    Article  PubMed  PubMed Central  Google Scholar 

  73. Sakai N, Nakamura M, Lipson KE, Miyake T, Kamikawa Y, Sagara A, Shinozaki Y, Kitajima S, Toyama T, Hara A, Iwata Y, Shimizu M, Furuichi K, Kaneko S, Tager AM, Wada T (2017) Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Sci Rep 7(1):5392

    Article  PubMed  PubMed Central  Google Scholar 

  74. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5(8):1428. https://doi.org/10.2215/CJN.09321209

    Article  CAS  Google Scholar 

  75. Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen V-TL, Koo CW, Sternlicht MD, Lipson KE (2016) FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition. Pharm Res 33(8):1849. https://doi.org/10.1007/S11095-016-1918-0

    Article  Google Scholar 

  76. Resovi A, Borsotti P, Ceruti T, Passoni A, Zucchetti M, Berndt A, Riser BL, Taraboletti G, Belotti D (2020) CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy. Cell 9(4):952

    Article  CAS  Google Scholar 

  77. Yamamoto T, Katayama I (2011) Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011:270938

    Article  PubMed  PubMed Central  Google Scholar 

  78. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K (1999) Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112(4):456–462

    Article  CAS  PubMed  Google Scholar 

  79. Yamamoto T (2017) Intradermal injections of Bleomycin to model skin fibrosis. Methods Mol Biol 1627:43–47

    Article  CAS  PubMed  Google Scholar 

  80. Braun RK, Ferrick DA, Sterner-Kock A, Kilshaw PJ, Hyde DM, Giri SN (1996) Comparison of two models of bleomycin-induced lung fibrosis in mouse on the level of leucocytes and T cell subpopulations in bronchoalveolar lavage. Comp Haematol Int 6:141–148

    Article  Google Scholar 

  81. Petrosino JM, Leask A, Accornero F (2019) Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle. FASEB J 33(2):2047–2057

    Article  CAS  PubMed  Google Scholar 

  82. Pi L, Robinson PM, Jorgensen M, Oh S-H, Brown AR, Weinreb PH, Trinh T le, Yianni P, Liu C, Leask A, Violette SM, Scott EW, Schultz GS, Petersen BE (2015) Connective tissue growth factor and integrin αvβ6: a new pair of regulators critical for Ductular reaction and biliary fibrosis. Hepatology 61(2):678–691

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Work in Dr. Leask’s lab is supported by the Arthritis Society, the Canadian Institutes of Health Research, and the Natural Sciences and Engineering Research Council of Canada.

Author information

Authors and Affiliations

  1. Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada

    Alexander Peidl

  2. College of Dentistry, University of Saskatchewan, Saskatoon, SK, Canada

    John Nguyen, Pratyusha Chitturi & Andrew Leask

  3. BLR Bio LLC, Kenosha, WI, USA

    Bruce L. Riser

  4. Center for Cancer Cell Biology, Immunology and Infection, Department of Physiology and Biophysics, and Department of Medicine Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

    Bruce L. Riser

Authors
  1. Alexander Peidl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pratyusha Chitturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce L. Riser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew Leask
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Leask .

Editor information

Editors and Affiliations

  1. Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School/Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    Masaharu Takigawa

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Peidl, A., Nguyen, J., Chitturi, P., Riser, B.L., Leask, A. (2023). Using the Bleomycin-Induced Model of Fibrosis to Study the Contribution of CCN Proteins to Scleroderma Fibrosis. In: Takigawa, M. (eds) CCN Proteins. Methods in Molecular Biology, vol 2582. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2744-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2744-0_21

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2743-3

  • Online ISBN: 978-1-0716-2744-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation